Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
Tóm tắt
Patients at increased risk of bleeding and recurrent VTE who develop venous thromboembolism (VTE) present challenges for clinical management. This study evaluated the effectiveness and safety of apixaban vs warfarin in patients with VTE who have risk factors for bleeding or recurrences. Adult patients with VTE initiating apixaban or warfarin were identified from five claims databases. Stabilized inverse probability treatment weighting (IPTW) was used to balance characteristics between cohorts for the main analysis. Subgroup interaction analyses were conducted to evaluate treatment effects among patients with and without each of the conditions that increased the risk of bleeding (thrombocytopenia and history of bleed) or recurrent VTE (thrombophilia, chronic liver disease, and immune-mediated disorders). A total of 94,333 warfarin and 60,786 apixaban patients with VTE met selection criteria. After IPTW, all patient characteristics were balanced between cohorts. Apixaban (vs warfarin) patients were at lower risk of recurrent VTE (HR [95% confidence interval (CI) 0.72 [0.67–0.78]), major bleeding (MB) (HR [95% CI] 0.70 [0.64–0.76]), and clinically relevant non-major (CRNM) bleeding (HR [95% CI] 0.83 [0.80–0.86]). Subgroup analyses showed generally consistent findings with the overall analysis. For most subgroup analyses, there were no significant interactions between treatment and subgroup strata on VTE, MB and CRNM bleeding. Patients with prescription fills for apixaban had lower risk of recurrent VTE, MB, and CRNM bleeding compared with warfarin patients. Treatment effects of apixaban vs warfarin were generally consistent across subgroups of patients at increased risk of bleeding/recurrences.
Tài liệu tham khảo
Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy. 2009;29(8):943–53. https://doi.org/10.1592/phco.29.8.943.
Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S–e496S. https://doi.org/10.1378/chest.11-2301.
Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–77. https://doi.org/10.2147/TCRM.S84210.
Greig SL, McKeage K. Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence. Drugs. 2014;74:1785–800. https://doi.org/10.1007/s40265-014-0304-7.
Deeks ED. Apixaban. Drugs. 2012;72:1271–91. https://doi.org/10.2165/11209020-000000000-00000.
Harder S. Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thrombosis J. 2014;12:22. https://doi.org/10.1186/1477-9560-12-22.
Poulakos M, Walker JN, Baig U, David T. Edoxaban: a direct oral anticoagulant. Am J Health Syst Pharm. 2017;74(3):117–29. https://doi.org/10.2146/ajhp150821.
Bracey A, Shatila W, Wilson J. Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence. Ther Adv Cardiovasc Dis. 2018;12(12):361–80. https://doi.org/10.1177/1753944718801554.
Klok FA, Kooiman J, Huisman MV, Konstantinides S, Lankeit M. Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. Eur Respir J. 2015;45(1):201–10. https://doi.org/10.1183/09031936.00040714.
Tamaki H, Khasnis A. Venous thromboembolism in systemic autoimmune diseases: a narrative review with emphasis on primary systemic vasculitides. Vasc Med. 2015;20(4):369–76. https://doi.org/10.1177/1358863X15573838.
Yusuf HR, Hooper WC, Grosse SD, Parker CS, Boulet SL, Ortel TL. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a US cohort of commercial insurance enrollees. Thromb Res. 2015;135(1):50–7. https://doi.org/10.1016/j.thromres.2014.10.012.
Brown JD, Goodin AJ, Lip G, Adams VR. Risk stratification for bleeding complications in patients with venous thromboembolism: application of the HAS-BLED bleeding score during the first 6 months of anticoagulant treatment. J Am Heart Assoc. 2018;7(6):e007901. https://doi.org/10.1161/JAHA.117.007901.
Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. New Engl J Med. 2013;369(9):799–808. https://doi.org/10.1111/jth.13153.
Coleman CI, Turpie AGG, Bunz TJ, Baker WL, Beyer-Westendorf J. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state. Thromb Res. 2018;163:132–7. https://doi.org/10.1016/j.thromres.2018.01.046.
Cohen A, Sah J, Lee T, et al. Effectiveness and safety of apixaban vs. warfarin in venous thromboembolism patients with obesity and morbid obesity. J Clin Med. 2021;10(2):200. https://doi.org/10.3390/jcm10020200.
Cohen AT, Sah J, Dhamane AD, et al. Effectiveness and safety of apixaban versus warfarin among older patients with venous thromboembolism with different demographics and socioeconomic status. Adv Ther. 2021;38(11):5519–33. https://doi.org/10.1007/s12325-021-01918-0.
Cohen AT, Sah J, Dhamane AD, et al. Effectiveness and safety of apixaban versus warfarin in venous thromboembolism patients with chronic kidney disease. Thromb Haemost. 2021. https://doi.org/10.1055/s-0041-1740254.
Weycker D, Li X, Wygant GD, et al. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. clinical practice. Thrombosis Haemost. 2018;118(11):1951–61. https://doi.org/10.1055/s-0039-3400530.
Hlavacek P, Guo JD, Rosenblatt L, et al. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population. Curr Med Res Opin. 2019;35(12):2043–51. https://doi.org/10.1080/03007995.2019.1653067.
Weycker D, Wygant GD, Guo JD, et al. Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses. Blood Adv. 2020;4(2):432–9. https://doi.org/10.1182/bloodadvances.2019001081.
Cohen AT, Keshishian A, Lee T, et al. Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: A US Claims data analysis. Thromb Haemost. 2020;121(3):383–95. https://doi.org/10.1055/s-0040-1718728.
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–79. https://doi.org/10.1002/sim.6607.
Thoemmes F, Ong AD. A primer on inverse probability of treatment weighting and marginal structural models. Curr Epidemiol Rep. 2017;4(1):40–59.
Xu S, Ross C, Raebel MA. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health. 2010;13(2):273–7. https://doi.org/10.1111/j.1524-4733.2009.00671.x.
Galloway J, Barrett K, Irving P, et al. Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study. RMD Open. 2020;6(3):e001392. https://doi.org/10.1136/rmdopen-2020-001392.
Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808. https://doi.org/10.1111/jth.13153.
Elsebaie M, van Es N, Langston A, Büller HR, Gaddh M. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. J Thromb Haemost. 2019;17(4):645–56. https://doi.org/10.1111/jth.14398.
Di Micco P, Monreal M. Platelet count and bleeding in patients receiving anticoagulant therapy for venous thromboembolism: lesson from the RIETE registry. J Blood Med. 2019;10:453–6. https://doi.org/10.2147/JBM.S234053.
Delate T, Hsiao W, Kim B, et al. Assessment of algorithms to identify patients with thrombophilia following venous thromboembolism. Thromb Res. 2016;137:97–102. https://doi.org/10.1016/j.thromres.2015.11.009.